This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ebert, O. Articles by Woo, S. L. C. Search for Related Content PubMed PubMed Citation Articles by Ebert, O. Articles by Woo, S. L. C.

Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-competent Rats¹

Carl C. Icahn Institute for Gene Therapy and Molecular Medicine [O. E., K. S., T-G. H., M. J. S., S. L. C. W.] and Department of Microbiology [A. G-S.], Mount Sinai School of Medicine, New York, New York 10029-6574

Tumor-targeted replicating viruses are being developed as a novel class of oncolytic agents. Vesicular stomatitis virus (VSV) is a negative-strand RNA virus with inherent specificity for replication in tumor cells due to their attenuated antiviral responses. VSV as an oncolytic virus is particularly appealing for its exceptionally rapid replication rate in tumor cells, such that the oncolytic effects could be maximally manifested before the onset of potentially neutralizing antiviral immune responses in the host. To easily monitor VSV replication, we have rescued a recombinant VSV (rVSV) vector expressing the green fluorescent protein (GFP) gene (rVSV-GFP). Using this GFP-expressing virus, we have demonstrated the oncolytic potential of VSV against human and rat hepatocellular carcinoma (HCC). We found that rVSV-GFP replicated efficiently in cultured human and rat HCC cells, whereas normal human and rat hepatocytes were refractory. When a single dose of the vector was injected intratumorally into large orthotopically implanted HCC in immune-competent rats, rVSV-GFP effectively and selectively replicated throughout the solid tumor mass without apparent hepatotoxicity, caused tumor destruction, and inhibited tumor growth, which led to significant prolongation of animal survival. Our results show that VSV is an effective oncolytic agent against HCC in immune-competent hosts and warrants further development for future therapy in patients with HCC.

This article has been cited by other articles:

				D. Dhar, J. F. Spencer, K. Toth, and W. S. M. Wold Effect of Preexisting Immunity on Oncolytic Adenovirus Vector INGN 007 Antitumor Efficacy in Immunocompetent and Immunosuppressed Syrian Hamsters J. Virol., March 1, 2009; 83(5): 2130 - 2139. [Abstract] [Full Text] [PDF]

				Q. Zhong, Y.-J. Wen, H.-S. Yang, H. Luo, A.-F. Fu, F. Yang, L.-J. Chen, X. Chen, X.-R. Qi, H.-G. Lin, et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice Ann. Onc., September 1, 2008; 19(9): 1584 - 1591. [Abstract] [Full Text] [PDF]

				C. Munoz-Fontela, S. Macip, L. Martinez-Sobrido, L. Brown, J. Ashour, A. Garcia-Sastre, S. W. Lee, and S. A. Aaronson Transcriptional role of p53 in interferon-mediated antiviral immunity J. Exp. Med., August 4, 2008; 205(8): 1929 - 1938. [Abstract] [Full Text] [PDF]

				S. Oliere, M. Arguello, T. Mesplede, V. Tumilasci, P. Nakhaei, D. Stojdl, N. Sonenberg, J. Bell, and J. Hiscott Vesicular Stomatitis Virus Oncolysis of T Lymphocytes Requires Cell Cycle Entry and Translation Initiation J. Virol., June 15, 2008; 82(12): 5735 - 5749. [Abstract] [Full Text] [PDF]

				Y. Wu, X. Lun, H. Zhou, L. Wang, B. Sun, J. C. Bell, J. W. Barrett, G. McFadden, J. A. Biegel, D. L. Senger, et al. Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1218 - 1227. [Abstract] [Full Text] [PDF]

				D. F. Gaddy and D. S. Lyles Oncolytic Vesicular Stomatitis Virus Induces Apoptosis via Signaling through PKR, Fas, and Daxx J. Virol., March 15, 2007; 81(6): 2792 - 2804. [Abstract] [Full Text] [PDF]

				M. Ahmed, K. L. Brzoza, and E. M. Hiltbold Matrix Protein Mutant of Vesicular Stomatitis Virus Stimulates Maturation of Myeloid Dendritic Cells J. Virol., March 1, 2006; 80(5): 2194 - 2205. [Abstract] [Full Text] [PDF]

				K. Shinozaki, O. Ebert, A. Suriawinata, S. N. Thung, and S. L. C. Woo Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats J. Virol., November 1, 2005; 79(21): 13705 - 13713. [Abstract] [Full Text] [PDF]

				W. Q. Yang, X. Lun, C. A. Palmer, M. E. Wilcox, H. Muzik, Z. Q. Shi, R. Dyck, M. Coffey, B. Thompson, M. Hamilton, et al. Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals: Racine and Nonhuman Primates Clin. Cancer Res., December 15, 2004; 10(24): 8561 - 8576. [Abstract] [Full Text] [PDF]

				J. H. Connor, C. Naczki, C. Koumenis, and D. S. Lyles Replication and Cytopathic Effect of Oncolytic Vesicular Stomatitis Virus in Hypoxic Tumor Cells In Vitro and In Vivo J. Virol., September 1, 2004; 78(17): 8960 - 8970. [Abstract] [Full Text] [PDF]

				O. Ebert, K. Shinozaki, C. Kournioti, M.-S. Park, A. Garcia-Sastre, and S. L. C. Woo Syncytia Induction Enhances the Oncolytic Potential of Vesicular Stomatitis Virus in Virotherapy for Cancer Cancer Res., May 1, 2004; 64(9): 3265 - 3270. [Abstract] [Full Text] [PDF]